Value Vs. Values: ICER’s Review Of Opioid Abuse-Deterrent Formulations
The Institute for Clinical & Economic Review is setting an appropriately broad scope in its review of the abuse-deterrent opioid class. But the project opens up a much larger question of how broadly to define value – and how to weigh non-economic values – in cost-effectiveness reviews.
You may also be interested in...
Abuse-Deterrent Opioids: ICER Value Analysis Could Reinforce Coverage Restrictions
Draft report concludes that added cost of abuse-deterrent opioids is not outweighed by reductions to health care system costs resulting from their use.
Abuse-Deterrent Opioids Effectiveness, Value To Get ICER Review
Pending arrival of several new products prompts evaluation of class, ICER CSO Dan Ollendorf explains; availability of both abuse-deterrent and non-abuse-deterrent drugs among challenging issues.
ICER Report Questions Cost-Effectiveness Of PD-1 Drugs In Lung Cancer
ICER report finds EGFR inhibitors are cost-effective in first-line non-small cell lung cancer, but PD-1/L1 inhibitors from Bristol, Merck and Roche may fall short in second-line treatment.